EBS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

EB

Mkt Cap

$326.9M

Volume

2.10M

Next Earnings

November 2nd

Loading chart

EB

EBSEmergent Biosolutions, Inc.

EBS

Pay with—

Available Balance0.00

EB

Mkt Cap

$368.1M

Volume

2.10M

Next Earnings

November 2nd

Chart Financials Earnings News About Insider Filings

Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?Emergent Biosolutions stock jumped 14.4% following positive news including a $24 million BARDA contract for Cyfendus, a three-year Canadian government contract for Narcan nasal spray, and a $75 million debt repurchase. However, the company faces headwinds with expected quarterly losses of $0.37 per share and revenues declining 46.6% year-over-year. With unchanged earnings estimates and a Zacks Rank #3 (Hold) rating, analysts question whether the rally can sustain.Zacks Investment Research · Oct 6, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSPomerantz LLP announced investigations into potential securities fraud at Emergent BioSolutions, Klarna Group, and Dr. Reddy's Laboratories. Emergent reported a $191.3 million impairment charge on its NARCAN asset group and cut full-year revenue guidance by 10.8%, citing increased competitive intensity. The stock fell 29.58% on the news.GlobeNewswire Inc. · Sep 23, 2026

Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS InsiderThe global intravenous immunoglobulin (IVIG) market is projected to grow from USD 14.98 billion in 2025 to USD 30.83 billion by 2035, at a CAGR of 7.49%. Growth is driven by expanding neurological indications, increased plasma collection capacity, and rising demand for immunoglobulin-based treatments. However, plasma supply dependency and a 100% U.S. tariff on imported IVIG products implemented in October 2025 pose significant constraints. North America leads the market, while Asia-Pacific shows the fastest growth.GlobeNewswire Inc. · Sep 10, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSPomerantz LLP is investigating potential securities fraud claims against Emergent BioSolutions following the company's August 5, 2026 earnings report. Emergent reported a $191.3 million non-cash impairment charge on its NARCAN asset group, resulting in a $180.2 million net loss, and cut full-year revenue guidance by 10.8%. The company attributed the decline to increased competitive intensity. Emergent's stock price fell 29.58% to $5.31 per share on August 6, 2026.GlobeNewswire Inc. · Sep 8, 2026

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray MultipacksEmergent BioSolutions announced FDA approval for new 6-count and 24-count multipack configurations of NARCAN® Nasal Spray, designed to improve distribution efficiency and accessibility for high-volume partners. The new formats will be available through NARCANDirect® and complement recent approval of a NARCAN® carrying case, supporting the company's efforts to combat opioid overdose deaths.GlobeNewswire Inc. · Feb 12, 2026

Lipid Nanoparticle Manufacturing Market: An 18.9% CAGR Market Driven by Nucleic Acid TherapiesThe global lipid nanoparticle (LNP) manufacturing market is valued at USD 565 million in 2026 and is expected to reach USD 2.24 trillion by 2034, growing at an 18.9% CAGR. North America currently dominates the market, while Asia-Pacific is experiencing notable expansion. Key growth drivers include mRNA vaccine development, precision medicine demand, and gene therapy applications. Solid lipid nanoparticles and nucleic acids segments lead current market share, while nanostructured lipid carriers and small molecules segments are expected to grow rapidly.GlobeNewswire Inc. · Jan 23, 2026

Biodefense Market to Attain USD 32.87 Billion by 2034, Driven by Biotech Advancements and Government FundingThe global biodefense market is projected to grow from USD 16.81 billion in 2024 to USD 32.87 billion by 2034, driven by advancements in biotechnology, increased government funding, and growing awareness of biological threats.GlobeNewswire Inc. · Oct 31, 2025

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene InternationalEmergent BioSolutions has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for approximately $36.5 million. The deal enables Emergent to streamline operations while maintaining flexibility for future product demand.Benzinga · Mar 19, 2025

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product CandidatesEmergent BioSolutions and Rocketvax have announced a strategic partnership, where Emergent will invest in Rocketvax and lead the U.S. manufacturing and commercialization of four of Rocketvax's pipeline candidates for infectious diseases, cancer, and autoimmune disorders.GlobeNewswire Inc. · Mar 12, 2025

Global Vaccine Contract Manufacturing Market to Boost with a Significant ~7% CAGR by 2032 | DelveInsightThe global vaccine contract manufacturing market is expected to grow significantly, driven by rising demand for immunization and the need for agile and scalable vaccine production, particularly in response to emerging infectious diseases.GlobeNewswire Inc. · Feb 24, 2025

to start trading

EB

EBSEmergent Biosolutions, Inc.

EBS

Pay with—

Available Balance0.00

Your PositionYou don't own any EBS yet.

Related Tickers

Earnings